NASDAQ$ALLO
Allogene Therapeutics Inc. · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2024 and provided corporate updates.
Allogene Therapeutics reported a net loss of $66.4 million for the second quarter of 2024 and ended the quarter with $444.6 million in cash, cash equivalents, and investments. The pivotal Phase 2 ALPHA3 trial was initiated in June 2024, and the IND application for ALLO-329 is on track for Q1 2025.
- Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024 for Cemacabtagene Ansegedleucel (Cema-Cel) in Large B-Cell Lymphoma (LBCL).
- Patient screening and enrollment for the ALPHA3 trial are proceeding as planned, with ten community and academic sites opened across the US.
- Investigational New Drug (IND) Application for ALLO-329 in Autoimmune Disease (AID) is on track for Q1 2025, with proof-of-concept data expected by YE 2025.
- A Phase 1 TRAVERSE data update for ALLO-316 in Renal Cell Carcinoma (RCC), including details on the diagnostic and treatment algorithm, is planned for YE 2024.
Headline financials
Revenue & EPS history
Allogene · Revenue · Quarterly
$0
Forward guidance
Allogene expects a decrease in cash, cash equivalents, and investments of approximately $200 million in 2024. GAAP Operating Expenses are expected to be approximately $300 million, including estimated non-cash stock-based compensation expense of approximately $60 million. These estimates exclude any impact from potential business development activities.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
+1.1%
Avg return
Earnings day
-2.7%
Avg return
5 days after
-5.0%
Avg return
30 days after
53%
16 / 30 earnings
Positive
+23.7%
Q3 2023
Best reaction
-11.8%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | -16.0% | -17.7% | |
| Q4 2025 | -2.8% | -13.0% | +10.1% | |
| Q3 2025 | +10.7% | +17.1% | +36.2% | |
| Q1 2025 | -1.8% | -1.8% | +23.4% | |
| Q4 2024 | +2.6% | -10.6% | -23.3% | |
| Q3 2024 | -4.3% | -11.8% | -32.0% | |
| Q2 2024 | -7.5% | -7.5% | -5.5% | |
| Q1 2024 | +7.2% | +0.4% | -6.9% | |
| Q4 2023 | -4.5% | -10.0% | -22.1% | |
| Q3 2023 | +23.7% | +15.9% | -11.0% | |
| Q2 2023 | +7.3% | -11.3% | -15.4% | |
| Q1 2023 | +20.6% | +18.1% | +4.9% | |
| Q4 2022 | +0.2% | -5.4% | -21.5% | |
| Q3 2022 | -9.9% | -14.2% | -10.5% | |
| Q2 2022 | +1.5% | +8.1% | -3.5% | |
| Q1 2022 | +2.3% | -18.9% | -8.0% | |
| Q4 2021 | -4.8% | -5.9% | -0.7% | |
| Q3 2021 | -0.1% | -5.8% | -12.6% | |
| Q2 2021 | +8.2% | +3.2% | +16.1% | |
| Q1 2021 | -0.7% | -1.4% | -19.0% | |
| Q4 2020 | +0.8% | +0.5% | -1.9% | |
| Q3 2020 | -11.8% | -17.5% | -0.4% | |
| Q2 2020 | +0.3% | -0.6% | -10.9% | |
| Q1 2020 | -0.9% | +8.2% | +38.1% | |
| Q4 2019 | +6.1% | +8.1% | -21.7% | |
| Q3 2019 | -10.5% | -5.5% | +2.1% | |
| Q2 2019 | +4.4% | -0.9% | -7.4% | |
| Q1 2019 | -2.1% | -2.5% | -16.5% | |
| Q4 2018 | -4.7% | -9.3% | -5.7% | |
| Q3 2018 | +3.8% | +8.3% | -5.5% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro